Skip to main content
SpringerLink
Log in

Therapy of Limited Stage Small Cell Lung Cancer

  • Chapter
Thoracic Oncology

Part of the book series: Cancer Treatment and Research ((CTAR,volume 105))

Abstract

Bronchogenic carcinoma is divided into two distinct entities, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) and these categories have distinguishing clinical, biologic, and histologic features. SCLC accounts for approximately 20% of the 164,000 cases of bronchogenic carcinoma expected to be diagnosed in the United States in 2000 (1). Until the late 1960’s, physicians did not differentiate the management of SCLC from NSCLC; in fact, clinical trials for lung cancer until the early 1970’s sometimes included both patient categories. It was recognized at that time, however, that most patients with SCLC had poor survival outcome with surgery and/or radiation and had little apparent survival benefit from either therapy. The breakthrough which occurred in the late 1960’s was the recognition that SCLC tumors were relatively more responsive to the available chemotherapeutic agents than NSCLC tumors (2). Since that time, it has been recognized that the standard of care for most SCLC patients has included systemic therapy in addition to locoregional therapy, if appropriate.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA: A Cancer Journal for Clinicians 50:7–33, 2000.

    Article  CAS  Google Scholar 

  2. Green, RA, Humprey, E, Close, H, et al. Alkylating agents in bronchogenic carcinoma. Am J Med 49:360–367, 1969.

    Google Scholar 

  3. Hirsch, FR, Matthews, MJ, Aisner, S, et al. Histopathologic classification of small cell lung cancer: Changing concepts and terminology. Cancer 62:973–977, 1988.

    Article  PubMed  CAS  Google Scholar 

  4. Hibi, K, Takahashi, T, Yamakawa, K, et al. Three distinct regions involved in 3p deletion in human lung cancer. Oncogene 7:445–449, 1992.

    PubMed  CAS  Google Scholar 

  5. Sozzi, G, Veroneses, ML, Negrini, M, et al. The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell 85:17–26, 1996.

    Article  PubMed  CAS  Google Scholar 

  6. Harbour, JW, Lai, SL, Whang-Peng, J, et al. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241:353–357, 1988.

    Article  PubMed  CAS  Google Scholar 

  7. Gazdar, AF. Molecular markers for the diagnosis and prognosis of lung cancer. Cancer 69:1592–1599, 1992.

    Article  PubMed  CAS  Google Scholar 

  8. Ben-Ezra, JM, Kornstein, MJ, Grimes, MM, et al. Small cell carcinomas of the lung express Bc1–2 protein. Am J pathol 145:1036–1040, 1994.

    PubMed  CAS  Google Scholar 

  9. Slebos, RJO, Kribbalaar, RE, Dadesic, O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323:561–565, 1990.

    Article  PubMed  CAS  Google Scholar 

  10. Gazdar, A. The molecular and cellular basis of human lung cancer. Anticancer Res 13:261–268, 1994.

    Google Scholar 

  11. Kelly, MJ, Linnoila, RI, Avis, IL, et al. Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest 112:256–261, 1997.

    Article  Google Scholar 

  12. Johnson, BE, Kelly, MJ. Autocrine growth factors and neuroendocrine markers in the development of small cell lung cancer. Oncology 12:11–14 (S1), 1998.

    PubMed  CAS  Google Scholar 

  13. List, AF, Hainsworth, JD, Devis, BV, et al. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small cell lung cancer. J Clin Oncol 4:1191–1198, 1986.

    PubMed  CAS  Google Scholar 

  14. Dimopoulos, MA, Fernandez, JF, Samaan, NA, et al. Paraneoplastic Cushing’s syndrome as an adverse prognostic factor in patients who die early with small cell carcinoma of the lung. Am J Med 77:851–857, 1984.

    Article  Google Scholar 

  15. Patel, AM, Davila, DG, Peters, SG. Paraneoplastic syndromes associated with lung cancer. Mayo Clin Proc 68:278–287, 1993.

    PubMed  CAS  Google Scholar 

  16. De La Monte, SM, Hutchins, GM, Moore, GW. Paraneoplastic syndromes and constitutional symptoms in prediction of metastatic behavior of small cell carcinoma of the lung. Am J Med 77:851–857, 1984.

    Article  PubMed  CAS  Google Scholar 

  17. Marchioli, CC, Graziano, SL. Paraneoplastic syndromes associated with small cell lung cancer. Chest Surg Clin North Am 7:65–80, 1997.

    CAS  Google Scholar 

  18. American Joint Committee on Cancer (AJCC). Manual for staging of cancer, 46 ed., pp127–137, Philadelphia, JB Lippincott, 1997.

    Google Scholar 

  19. Stahel, RA, Ginsberg, R, Havermann, K, et al. Staging and prognostic factors in small cell lung cancer: A consensus. Lung Cancer 5:119–126, 1989.

    Article  Google Scholar 

  20. Albain, KS, Crowley, JJ, LeBlanc, M, et al. Determinants of improved outcome in small cell lung cancer: An analysis of the 2,580-patient Southwest Oncology Group database. J Clin Oncol 8:1563–1574, 1990.

    PubMed  CAS  Google Scholar 

  21. Souhami, RL, Bradbury, I, Geddes, OM, et al. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res 45:2878–2882, 1985.

    PubMed  CAS  Google Scholar 

  22. Cerny, T, Blair, V, Anderson, H, et al. Pretreatment prognostic factors and scoring system in 407 small cell lung cancer patients. Int J Cancer 39:146–149, 1987.

    Article  PubMed  CAS  Google Scholar 

  23. Edmondson, JH, Lagakos, SW, Selawry, OS, et al. Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung. Cancer Treatment Rep 60:925–932, 1976.

    Google Scholar 

  24. Lowenbraun, S, Bartolucci, A, Smalley, RV, et al. The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. Cancer 44:406–413, 1979.

    Article  PubMed  CAS  Google Scholar 

  25. Souhami, RI, Geddes, DM, Spiro, SG, et al. Radiotherapy in small cell cancer of the lung treated with combination chemotherapy: A controlled trial. Br J Med 288:1643–1646, 1984.

    Article  CAS  Google Scholar 

  26. Byhardt, RW, Cox, JD, Holoye, PY, et al. The role of consolidation irradiation in combined modality therapy of small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 8:1271–1276,1982.

    Article  PubMed  CAS  Google Scholar 

  27. Perry, M, Eaton, WC, Propert, KJ, et al. Chemotherapy with or without radiation therapy in limited small-cell lung cancer. N Eng J Med 316:912–918, 1987.

    Article  CAS  Google Scholar 

  28. Bunn, PA, Lichter, AS, Makuch, RW, et al. Chemotherapy alone or chemotherapy with chest radiation therapy in limited-stage small-cell lung cancer. Ann Intern Med 106:655–662, 1987.

    PubMed  Google Scholar 

  29. Perez, CA, Krauss, S, Bartolucci, AA, et al. Thoracic and elective brain irradiation with concomitant or delayed multiagent chemotherapy in the treatment of localized small cell carcinoma of the lung: a randomized prospective study by the Southeastern Cancer Study Group. Cancer 47:2407–2413, 1981.

    Article  PubMed  CAS  Google Scholar 

  30. Pignon, JP, Arrigada, R, Ihde, D. Meta-analysis of small-cell lung cancer. N Eng J Med 327:1618–1624, 1992.

    Article  CAS  Google Scholar 

  31. Warde, P, Payne, D. Does thoracic irradiation improve survival and local control in limited-stage small cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10:890–895, 1992.

    PubMed  CAS  Google Scholar 

  32. Murray, N, Coy, P, Pater, JL, et al. The importance of timing of thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 11:336–344, 1993.

    PubMed  CAS  Google Scholar 

  33. Goto, K, Nishiwaki, Y, Takada, M, et al. Final results of a phase III study of concurrent vs sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited stage small-cell lung cancer: The Japan Clinical Oncology Group Study. Proc Am Soc Clin Oncol 18:468a, 1999 (Abstr).

    Google Scholar 

  34. Work, E, Nielson, O, Bentzen, S, et al. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small cell lung cancer. J Clin Oncol 15:3030–3037, 1997.

    PubMed  CAS  Google Scholar 

  35. Schultz, HP, Neilson, OS, Sell, A, et al. Timing of chest radiation with respect to combination chemotherapy in small cell lung cancer, limited disease. Lung Cancer 4:153, 1988 (Abstr).

    Google Scholar 

  36. Jeremic, B, Shibamoto, Y, Acimovic, L, et al. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited stage small cell lung cancer: A randomized study. J Clin Oncol 15:893–900, 1997.

    PubMed  CAS  Google Scholar 

  37. Carlson, RW, Sikic, BI, Gandara, DR et al. Late consolidative radiation therapy in the treatment of limited-stage small cell lung cancer. Cancer 68;948–958, 1991.

    Article  PubMed  CAS  Google Scholar 

  38. Kies, MS, Mira, JG, Crowley, JJ, et al. Multimodal therapy for limited small cell lung cancer: A randomized trial of induction combination chemotherapy with or without thoracic irradiation in complete responders: and with wide field versus reduced field in partial responders: A Southwest Oncology Group Trial. J Clin Oncol 5:592–600, 1987.

    PubMed  CAS  Google Scholar 

  39. Lebeau, B, Chastang, C, Brechot, JM, et al. A randomized trial of delayed radiotherapy in complete responder patients with small cell lung cancer. Chest 104:726–733, 1993.

    Article  PubMed  CAS  Google Scholar 

  40. Murray, N. Treatment of small cell lung cancer: the state of the art. Lung Cancer 17 Supp1.1:75–89, 1997.

    Article  Google Scholar 

  41. Choi, N, Carey, R. Importance of radiation dose in achieving improved loco-regional tumor control in limited stage small cell lung carcinoma: An update. Int J Radiat Oncol Biol Phys 17:307–310, 1989.

    Article  PubMed  CAS  Google Scholar 

  42. Coy, P, Hodson, I, Payne, D, et al. The effect of dose of thoracic irradiation on recurrence in patients with limited stage small cell lung cancer. Initial results of a Candian multicenter randomized trial.. Int J Radiat Oncol Biol Phys 14:219226, 1988.

    Google Scholar 

  43. Lichter, AS, Turrisi, AT. Small-cell lung cancer: The influence of dose and treatment volume on outcome. Semin Radiat Oncol 5:44–49, 1995.

    Article  PubMed  Google Scholar 

  44. PapacRJSon, Y, Bien, R, et al. Improved local control of thoracic disease in small cell lung cancer with higher dose thoracic irradiation and cyclic chemotherapy. Int J Radiat Oncol Biol Phys 13:993–998, 1987.

    Article  PubMed  CAS  Google Scholar 

  45. Shank, B, Scher, H, Hilaris, BS, et al. Increased survival with high-dose multifield radiotherapy and intensive chemotherapy in limited small cell carcinoma of the lung. Cancer 56:2771–2778, 1985.

    Article  PubMed  CAS  Google Scholar 

  46. Komaki, R, Shin, DM, Glisson, BS, et al. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer/ Int J Radiat Oncol Biol Phys 31:807–811, 1995.

    Article  PubMed  CAS  Google Scholar 

  47. Armstrong, J, Shank, B, Scher, H, et al. Limited small cell lung cancer: Do favorable short-term results predict ultimate outcome? Am J Clin Oncol 14:285290, 1991.

    Google Scholar 

  48. Choi, N, Herndon, J, Rosenman, J, et al. Phase I study to determine the maximum tolerated dose of radiation in standard daily and accelerated twice daily radiotherapy schedules with concurrent chemotherapy for limited stage small lung cancer: CALGB 8837. J Clin Onco116:3528–3536, 1998.

    Google Scholar 

  49. Turrisi, AT, Glover, DJ, Mason, B, et al. Concurrent twice-daily multi-field radiotherapy and platinum-etoposide chemotherapy for limited small-cell lung cancer: Update 1987 (Abstract). Proc Am Soc Clin Oncol 6:172, 1987.

    Google Scholar 

  50. Johnson, DH, Turrisi, AT, Chang, AY, et al. Alternating chemotherapy and twice-daily thoracic radiotherapy in limited small cell lung cancer: A pilot study of the Eastern Cooperative Oncology Group. J Clin Oncol 11:879–884, 1993.

    PubMed  CAS  Google Scholar 

  51. Turrisi, A, Kim, K, Blum, R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265–71, 1999.

    Article  PubMed  CAS  Google Scholar 

  52. Bonner, JA, Slaon, JA, Shanahan, TG, et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung cancer. J Clin Oncol 17:2681–2691, 1999.

    PubMed  CAS  Google Scholar 

  53. Eaton, W, Maurer, H, Glicksman, A, et al. The relationship of infield recurrences to prescribed tumor dose in small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 7:1223, 1981 (Abstr).

    Article  Google Scholar 

  54. White, J, Chen, R, McCracken, J, et al. The influence of radiation therapy quality control on survival, response, and sites of relapse in oat cell carcinoma of the lung: Preliminary report of a SWOG study. Cancer 50:1084–1090, 1982.

    Article  PubMed  CAS  Google Scholar 

  55. Mira, JG, Livingston: Evaluation and radiotherapy implications of chest relapse patterns in small cell lung carcinoma treated with radiotherapy-chemotherapy: Study of 34 cases and review of the literature. Cancer 46:2557–2565, 1980.

    Article  PubMed  CAS  Google Scholar 

  56. Liengswangwong, V, Bonner, JA, Shaw, EG, et al. Limited-stage small cell lung cancer: Patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. J Clin Oncol 12:496–502, 1994.

    PubMed  CAS  Google Scholar 

  57. Kies, MS, Mira, JG, Crowley, JJ, et al. Multimodal therapy for limited small cell lung cancer: A randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: A Southwest Oncology Group study. J Clin Oncol 5:592–600, 1987.

    PubMed  CAS  Google Scholar 

  58. Brodin, O, Rikner, G, Steinholtz, L, et al. Local failure in patients treated with radiotherapy and multidrug chemotherapy for small cell lung cancer. Acta Oncol 29:739–746, 1990.

    Article  PubMed  CAS  Google Scholar 

  59. Sierocki, JS, Hilaris, BS, Hopfan, S, et al. Cis-dichlorodiammineplatinum (II) and VP-16–213: An active induction regimen for small cell carcinoma of the lung. Cancer Treat Rep 63:1593–1597, 1979.

    PubMed  CAS  Google Scholar 

  60. Roth, BJ, Johnson, DH, Einhorn, LH. Randomized study of cyclohosphamide plus doxorubicin plus vincristine versus etoposide plus cisplatin versus alternation of these two regimens in extensive small cell lung cancer: a phase II study of the Southeastern Cancer Study Group. J Clin Oncol 10:282–291, 1992.

    PubMed  CAS  Google Scholar 

  61. Fukuoka, M, Furuse, K, Saijo, N. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer. J Nat Cancer Inst 83:855–861, 1991.

    Article  PubMed  CAS  Google Scholar 

  62. Postmus, P, Smit, EF. Small cell lung cancer: Is there a standard therapy? Oncology 12(S2):25–30, 1998.

    PubMed  CAS  Google Scholar 

  63. MacCracken, JD, Janaki, LM, Crowley, JJ, et al. Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: A Southwest Oncology Group study. J Clin Oncol 8:892–898, 1990.

    Google Scholar 

  64. Johnson, BE, Salem, C, Nesbitt, J, et al. Limited stage small cell lung cancer treated with concurrent BID chest radiotherpy and etoposide/cisplatin followed by chemotherapy selected by in vitro drug sensitivity testing. Proc Amer Assoc Clin Oncol 10:240, 1991.

    Google Scholar 

  65. Murray, N. Treatment of small cell lung cancer: the state of the art. Lung Cancer 17 (S1) S75–89, 1997.

    Article  PubMed  Google Scholar 

  66. Cohen, MH, Creaven, PJ, Fossiak, BE. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 9:499–508, 1997.

    Google Scholar 

  67. Mehta, C, Vogl, SE, et al. High-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small cell lung cancer: minor improvements in the rate of remission and survival. Proc Am Assoc Cancer Res 23:155, 1982 (Abstr).

    Google Scholar 

  68. LeChevalier, T, Arrigada, R, Pignon, J. Initial chemotherapy doses have a significant impact on survival fin limited small cell lung cancer: Results of a multicentre prospective randomized study in 105 patients. N Engl J Med 329:1848–1852, 1993.

    Article  Google Scholar 

  69. Loehrer, P, Ansari, R, Gonin, R, et al. Cisplatin plus etoposide with and without ifosfamide in extensive stage small cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 13:2494–2499, 1995.

    Google Scholar 

  70. Glisson, B, Scott, C, Komaki, R, et al. Cisplatin, ifosfamide, prolonged oral etoposide, and concurrent accelerated hyperfractionated thoracic radiotherapy for patients with limited small cell lung cancer: Proc Am Soc Clin Oncol 11:336–344, 1998.

    Google Scholar 

  71. Ettinger, DS, Seiferheld, WF, Abrams, R, et al. Cisplatin, etoposide, paclitaxel, and concurrent hyperfractionated thoracic radiotherapy for patients with limited disease small cell lung cancer: Preliminary results of RTOG 96–09. Proc Am Soc Clin Oncol 19:490a, 2000 (Abstr).

    Google Scholar 

  72. Ettinger, DS, Finkelstein, DM, Sarma, RP, et al. Phase II study of paclitaxel in patients with extensive stage small cell lung cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 13:1430–1435, 1995.

    PubMed  CAS  Google Scholar 

  73. Hainsworth, JD, Hopkins, LG, Thomas, M, et al. Paclitaxel, carboplatin, and extended-schedule oral etoposide for small cell lung cancer. Oncology 12(S2):3135, 1998.

    Google Scholar 

  74. Hainsworth, J,Gray, J,Stroup, S, et al. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: Comparison of sequential phase II trials using different dose levels. J Clin Oncol 15:3464–3470, 1997.

    PubMed  CAS  Google Scholar 

  75. Ardizzoni, A, Hansen, H, Dombernowsky, P et al. Topotecan, a new active drug in the second-line treatment of small cell lung cancer: A phase II study in patients with refractory and sensitive disease. J Clin Oncol 15:2090–2096, 1997.

    PubMed  CAS  Google Scholar 

  76. Masuda, N, Fukuka, M, Kusunoki, Y, et al. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small cell lung cancer. J Clin Oncol 10:1225–1229, 1992.

    PubMed  CAS  Google Scholar 

  77. Smyth, JF, Smith, IE, Seesa, C, et al. Activity of docetaxel (Taxotere) in small cell lung cancer. Eur J Cancer 30A:1058–1060, 1994.

    Article  PubMed  CAS  Google Scholar 

  78. Abratt, R, Bezwoda, WR, Goedhals, W, et al. Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non-small cell lung cancer. J Clin Oncol 15:744–749, 1997.

    PubMed  CAS  Google Scholar 

  79. Evans, WK, Radwi, J, Tomiak, E, et al. Oral etoposide and carboplatin: Effective therapy for elderly patients with small cell lung cancer. Am J Clin Oncol 18:149155, 1995.

    Google Scholar 

  80. Ettinger, DS. Evaluation of new drugs in untreated patients with small-cell lung cancer: Its time has come (Comment). J Clin Oncol 8:374–377, 1990.

    PubMed  CAS  Google Scholar 

  81. Noda, K, Nishiwaki, Y, Kawahara, S, et al. Randomized phase III study of irinotecan and cisplatin versus etoposide and cisplatin in extensive-disease small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG 9511). Proc Am Soc Clin Oncol 19:482a, 2000 (Abstr).

    Google Scholar 

  82. Fox, W, Scadding, JG. Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of the bronchus: Ten year follow-up. Lancet 2:63–5, 1973.

    CAS  Google Scholar 

  83. Shields, TW, Higgins, GA, Matthews, MJ, et al. Surgical resection in the management of small cell lung cancer. J Thorac Cardiovas Surg 84:481–488, 1982.

    CAS  Google Scholar 

  84. Friess, GG, McCracken, JD, Troxell, MJ, et al. Effect of initial resection of small cell carcinoma of the lung: A review of Southwest Oncology Group study 7628. J Clin Oncol 3:9644–968, 1985.

    Google Scholar 

  85. Ichonose, Y, Hara, N, Ohta, M, et al. Comparison between resected and irradiated small cell lung cancer in patients in stage I through IIIa. Ann Thorac Surg 53:95100, 1992.

    Google Scholar 

  86. Prager, RL, Foster, JM, Hainsworth, JM, et al. The feasibility of adjuvant surgery in limited stage small cell carcinoma: a prospective evaluation. Ann Thorac Surg 38:622–625, 1984.

    Article  PubMed  CAS  Google Scholar 

  87. Shepherd, FA, Ginsberg, RJ, Patterson, GA, et al. A prospective study of adjuvant surgical resection after chemotherapy for limited small cell lung cancer: A University of Toronto Lung Oncology Group study. J Thorac Cardiovasc Surg 97:177–186, 1989.

    PubMed  CAS  Google Scholar 

  88. Baker, RR, Ettinger, DS, Ruckdeschel, JD. The role of surgery in the management of selected patients with small cell cancer of the lung. J Clin Oncol 5:697–702, 1987.

    PubMed  CAS  Google Scholar 

  89. Lad, T, Piantadosi, S, Thomas, P, et al. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell llung cancer to combination chemotherapy. Chest 106:320–323, 1994.

    Article  Google Scholar 

  90. Shepherd, FA, Ginsberg, R, Patterson, GA, et al. Is there ever a role for salvage operations in limited small cell lung cancer? J Thorac Cardiovasc Surg 101:196200, 1991.

    Google Scholar 

  91. Bleyer, WA, Poplack, DG, et al. Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Semin Oncol 12:131–148, 1985.

    PubMed  CAS  Google Scholar 

  92. Gregor, A. Prophylactic cranial irradiation in small cell lung cancer: Is it ever indicated? Oncology 12:19–24, 1998.

    PubMed  CAS  Google Scholar 

  93. Johnson, BE, Becker, B, Geoff, WB, et al. Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2 to 10 year survivors of small cell lung cancer. J Clin Oncol 3:1659–1667, 1985.

    PubMed  CAS  Google Scholar 

  94. Catane, R, Schwade, JG, Varr, I, et al. Follow-up neurologic evaluation in patients with small cell lung carcinoma treated with prophylactic cranial irradiation and chemotherapy. Int J Radiat Oncol Biol Phys 7:105–109, 1981.

    Article  PubMed  CAS  Google Scholar 

  95. Arriagada, R, LeCahvalier, T, Borie, F, et al. Prophlactic cranial irradiation for patients with small cell lung cancer in complete remission. J Nat Cancer Inst 87:183–190, 1995.

    Article  PubMed  CAS  Google Scholar 

  96. Gregor, A, Cull, A,Stephens, RJ, et al. Prophylactic cranial irradiation as indicated following complete response to induction therapy in small cell lung cancer: Results of a multicentre randomised trial. Eur J Cancer 33:1752–1758, 1997 (supp 11).

    CAS  Google Scholar 

  97. Auperin, A, Arriagada, R, Pignon, JP, et al. Prophylactic cranial irradiation in patients with small cell lung cancer in complete remission. N Engl J Med 341:476–484, 1999.

    Article  PubMed  CAS  Google Scholar 

  98. Sandler A, Declerck L, Wagner H, et al. A phase II study of cisplatin plus etoposide plus paclitaxel and concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): An Eastern Cooperative Oncology Group Trial. Proc Am Soc Clin Oncol 19:491a, 2000 (Abstr).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kimmel Cancer Center of Jefferson Medical College, Philadelphia, PA, 19107, USA

    M.D Walter J. Curran Jr.

Authors
  1. M.D Walter J. Curran Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Johns Hopkins Oncology Center, Bunting Blaustein Cancer Research Building, Baltimore, Maryland, USA

    David S. Ettinger MD

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Curran, W.J. (2001). Therapy of Limited Stage Small Cell Lung Cancer. In: Ettinger, D.S. (eds) Thoracic Oncology. Cancer Treatment and Research, vol 105. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1589-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-1589-0_9

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5629-5

  • Online ISBN: 978-1-4615-1589-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation